Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients - Contacts and Locations

Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients

This study has been completed.

Study NCT00034255. Last updated on June 23, 2005. Information provided by GMP Endotherapeutics

Please refer to this study by its ClinicalTrials.gov identifier: NCT00034255

Locations


United States, California
	VASDHS Medical Center
	San Diego, California, United States, 92161

United States, District of Columbia
	MedStar Research Institute - Clinical Research Center
	Washington, District of Columbia, United States, 20003

United States, North Carolina
	UNC Diabetes, Endocrinology, Metabolism Clinic
	Durham, North Carolina, United States, 27713

United States, Texas
	Texas Diabetes Institute
	San Antonio, Texas, United States, 78284

Sponsors and Collaborators

GMP Endotherapeutics